Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis

Italfarmaco1 enrolled

Overview

Primary Objective of the study: the purpose of this extension study was to determine the safety of Givinostat in a long term treatment of patients who participated in DSC/08/2357/36 study with good results (clinical benefit at least pediACR30 response);

Givinostat is expected to exert a clinically relevant therapeutic effect on polyarticular JIA through the inhibition of the production/release of pro-inflammatory cytokines, such as IL-1β, IL-6 and TNFα, which are involved in the pathogenesis of the arthritic process.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Juvenile Idiopathic Arthritis

Interventions

GivinostatDRUG

ready-to-use oral suspension, administered in fed condition and on a outpatient basis, especially intended for paediatric patients

Eligibility

Sex: ALLMin age: 2 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * subjects who had successfully completed the previous Dose Finding Study and were fully compliant to the inclusion/exclusion criteria described in the previous DSC/08/2357/36 Exclusion Criteria: * patients with fever related to JIA or other systemic features of JIA during 12 months before entering the study * active bacterial or mycotic infection requiring antimicrobial treatment * episode of macrophage activation syndrome over the last 6 months * baseline prolongation of QT/QTc interval, use of concomitant medications that prolong the QT/QTc interval or history of additional risk factors for TdP. * clinically significant cardiovascular disease * clinically significant illness i.e. any condition that in the opinion of the Investigator places the patient to unacceptable risk for adverse outcome if he/she were to participate in the study * psychiatric illness/social situation that would limit compliance with study medication and protocol requirements * inherited metabolic diseases * presence of malignancy * pregnancy or lactation * positive blood test for HIV * active EBV infection, active B and/or C hepatitis * platelet count \<100x10(9)/L

Locations (1)

1st Faculty of Medicine and General Faculty Hospital

Prague, Czechia

Outcomes

Primary Outcomes

Number of Participants With Serious Adverse Events (SAE) and Adverse Events (AE) of Interest

During the entire study period it was reported only one adverse event considered not drug related by the investigator (Mild flu at week 107 of study treatment). No action was taken and the patient recovered spontaneously

Time frame: Through end of treatment, up to 108 weeks.

Secondary Outcomes

Number of Patients Who Maintained PedACR30 Response

This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30). PedACR30 is defined as at least a 30% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%: * physician's global assessment of disease activity; * parent/guardian's or patient's global assessment of overall wellbeing; * functional ability; * number of joints with active arthritis; * number of joints with limited range of motion; * ESR. (ACR stands for American College of Rheumatology)

Time frame: At weeks 48, 60 and 108

Number of Patients Who Reached PedACR70 Response

This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30). PedACR70 is defined as at least a 70% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%: * physician's global assessment of disease activity; * parent/guardian's or patient's global assessment of overall wellbeing; * functional ability; * number of joints with active arthritis; * number of joints with limited range of motion; * ESR. (ACR stands for American College of Rheumatology)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.